PacBio alleged in its suit that Oxford Nanopore is infringing on a patent it holds related to single-molecule nanopore sequencing.
PacBio recently launched a new sequencing chemistry for Sequel that increases read lengths, and plans to double the platform's throughput by the end of the year.
Pacific Biosciences nearly doubled its product and services revenue due to sales of its Sequel instrument.
Roche said the timeline to launch a diagnostic system and assays based on PacBio's technology would be too long; instead, it will focus on commercializing Genia's technology.
The two companies struck a $75 million deal in 2013 to launch a sequencing system and assays for the diagnostic market.
PacBio's product revenues increased due to sales of its Sequel system. The company also alleged that Oxford Nanopore's products infringe on a patent it holds.
The company plans to raise $25 million in a Series B financing round. It is also working on a two-color chemistry and aims to develop an instrument for clinical applications.
The researchers have generated the most contiguous de novo assembly of a human genome to date and plan to use it as a reference for population sequencing projects.
During a live webcast, CTO Clive Brown provided an update on the company's development plans and upcoming updates.
The firm expects throughput and performance of Sequel to increase as it transitions to a high-volume SMRT chip manufacturer and with its new instrument updates.
Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.
An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.
The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.
In Nature this week: genotypes linked to hip osteoarthritis, and more.